Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update
about
Everolimus in Combination with Octreotide Long-Acting Repeatable in a First-Line Setting for Patients with Neuroendocrine Tumors: A 5-Year Update
description
im Januar 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 26 July 2017
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2018
@uk
name
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@en
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@nl
type
label
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@en
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@nl
prefLabel
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@en
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@nl
P2093
P356
P1433
P1476
Everolimus in Combination with ...... ocrine Tumors: A 5-Year Update
@en
P2093
Anna Maria Marte
Claudio Iannacone
Emilio Bajetta
Francesca Spada
Giandomenico Di Menna
Italo Sarno
Laura Catena
Lorenzo Dottorini
P304
P356
10.1159/000479587
P407
P577
2017-07-26T00:00:00Z